Biogen Inc.
MX ˙ BMV ˙ US09062X1037
SecurityMX:BIIB / Biogen Inc.
InstitutionPhoenix Holdings Ltd.
Latest Disclosed Ownership1,371 shares
Latest Disclosed Value $ 251,345
Phoenix Holdings Ltd. reports 56.24% decrease in ownership of BIIB / Biogen Inc.

On May 11, 2026 - Phoenix Holdings Ltd. filed a 13F-HR form disclosing ownership of 1,371 shares of Biogen Inc. (MX:BIIB) valued at $251,345 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 5, 2026 disclosing 3,133 shares of Biogen Inc.. This represents a change in shares of -56.24% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F BIOGEN COM 09062X103 1,371 -1,762 -56.24 251 -54.45 0.0015
2026-02-05 2025-12-31 13F BIOGEN COM 09062X103 3,133 3,133 551 0.0038
2025-05-07 2025-03-31 13F BIOGEN COM 09062X103 0 -3,608 -100.00 0 -100.00
2025-02-13 2024-12-31 13F BIOGEN COM 09062X103 3,608 3,608 552 0.0075
2024-05-15 2024-03-31 13F BIOGEN COM 09062X103 0 -760 -100.00 0 -100.00
2024-02-14 2023-12-31 13F BIOGEN COM 09062X103 760 760 207 0.0034
2023-12-04 2023-09-30 13F/A-2 BIOGEN COM 09062X103 0 -2,194 -100.00 0 -100.00
2023-12-04 2023-09-30 13F/A-1 BIOGEN COM 09062X103 0 0
2023-11-13 2023-09-30 13F BIOGEN COM 09062X103 0 -2,194 0
2023-08-07 2023-06-30 13F BIOGEN COM 09062X103 2,194 2,194 618 0.0126
2022-05-10 2022-03-31 13F BIOGEN COM 09062X103 0 -1,332 -100.00 0 -100.00
2022-02-07 2021-12-31 13F BIOGEN COM 09062X103 1,332 -202 -13.17 319 -27.00 0.0053
2021-10-27 2021-09-30 13F BIOGEN COM 09062X103 1,534 1,534 437 0.0076
2021-08-10 2021-06-30 13F BIOGEN COM 09062X103 0 -1,849 -100.00 0 -100.00
2021-05-10 2021-03-31 13F BIOGEN COM 09062X103 1,849 519 39.02 510 57.89 0.0115
2021-02-11 2020-12-31 13F BIOGEN COM 09062X103 1,330 -7,416 -84.79 323 -86.14 0.0087
2020-11-10 2020-09-30 13F BIOGEN COM 09062X103 8,746 1,795 25.82 2,330 35.15 0.0975
2020-08-10 2020-06-30 13F BIOGEN COM 09062X103 6,951 -5 -0.07 1,724 -19.21 0.0731
2020-05-20 2020-03-31 13F BIOGEN COM 09062X103 6,956 6,956 2,134 0.1081
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.